MicroRNAs (miRNAs) are emerging as biomarkers for the detection and prognosis of
cancers due to their inherent stability and resilience. To summarize the evidence regarding …

Bladder cancer is one of the most financially burdensome cancers globally, from its
diagnostic to its terminal stages. The impact it imposes on patients and the medical …

During the last decades, male urogenital cancers (including prostate, renal, bladder and
testicular cancers) have become one of the most frequently encountered malignancies …

Non-muscle invasive bladder cancer (NMIBC) accounts for~ 70–75% of total bladder cancer
tumors and requires effective early intervention to avert progression. The cornerstone of high …

Bladder cancer is an increasingly prevalent global disease that continues to cause morbidity
and mortality despite recent advances in treatment. Immune checkpoint inhibitors (ICI) and …

The treatment of metastatic urothelial carcinoma has dramatically changed over the past
decade with the approval of several therapies from multiple drug classes including immune …

Bladder cancer is one of the most common cancers worldwide, with 213 000 deaths
reported in 2020. Patients with a progression from non-muscle-invasive bladder cancer to …

Bladder cancer, the most common malignancy of the urinary tract, has a poor overall survival
rate when the tumor becomes muscle invasive. The discovery and evaluation of new …

Treatment of bladder cancer remains a critical unmet need and requires advanced
approaches, particularly the development of local drug delivery systems. The physiology of …

Bladder cancer ranks as the 10th most prevalent cancer globally with an increasing
incidence. Radical cystectomy combined with urinary diversion represents the standard …